vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Veris Residential, Inc. (VRE). Click either name above to swap in a different company.
Veris Residential, Inc. is the larger business by last-quarter revenue ($70.1M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). Veris Residential, Inc. runs the higher net margin — -20.0% vs -83.0%, a 63.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 3.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 1.9%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Veris Residential, Inc. is an American real estate investment trust headquartered in Jersey City, New Jersey, investing primarily in apartments in New Jersey and Boston.
RYTM vs VRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $70.1M |
| Net Profit | $-47.5M | $-14.0M |
| Gross Margin | 91.6% | 95.9% |
| Operating Margin | -82.2% | -22.2% |
| Net Margin | -83.0% | -20.0% |
| Revenue YoY | 36.9% | 3.5% |
| Net Profit YoY | -9.6% | -30.9% |
| EPS (diluted) | $-0.73 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $70.1M | ||
| Q4 25 | $57.3M | $71.3M | ||
| Q3 25 | $51.3M | $73.4M | ||
| Q2 25 | $48.5M | $75.9M | ||
| Q1 25 | $32.7M | $67.8M | ||
| Q4 24 | $41.8M | $68.1M | ||
| Q3 24 | $33.3M | $68.2M | ||
| Q2 24 | $29.1M | $67.5M |
| Q1 26 | — | $-14.0M | ||
| Q4 25 | $-47.5M | $-203.0K | ||
| Q3 25 | $-52.9M | $75.2M | ||
| Q2 25 | $-46.6M | $10.9M | ||
| Q1 25 | $-49.5M | $-10.7M | ||
| Q4 24 | $-43.3M | $-12.4M | ||
| Q3 24 | $-43.6M | $-9.7M | ||
| Q2 24 | $-32.3M | $2.9M |
| Q1 26 | — | 95.9% | ||
| Q4 25 | 91.6% | 97.2% | ||
| Q3 25 | 89.3% | 96.8% | ||
| Q2 25 | 88.6% | 97.2% | ||
| Q1 25 | 88.8% | 95.9% | ||
| Q4 24 | 90.9% | 97.1% | ||
| Q3 24 | 88.5% | 96.9% | ||
| Q2 24 | 89.9% | 97.3% |
| Q1 26 | — | -22.2% | ||
| Q4 25 | -82.2% | -0.9% | ||
| Q3 25 | -102.6% | — | ||
| Q2 25 | -93.4% | 15.8% | ||
| Q1 25 | -143.7% | -20.4% | ||
| Q4 24 | -98.6% | -21.9% | ||
| Q3 24 | -132.0% | -16.2% | ||
| Q2 24 | -139.2% | 2.2% |
| Q1 26 | — | -20.0% | ||
| Q4 25 | -83.0% | -0.3% | ||
| Q3 25 | -103.1% | 102.4% | ||
| Q2 25 | -96.1% | 14.4% | ||
| Q1 25 | -151.4% | -15.8% | ||
| Q4 24 | -103.6% | -18.3% | ||
| Q3 24 | -131.2% | -14.2% | ||
| Q2 24 | -110.9% | 4.3% |
| Q1 26 | — | $-0.15 | ||
| Q4 25 | $-0.73 | $0.00 | ||
| Q3 25 | $-0.82 | $0.80 | ||
| Q2 25 | $-0.75 | $0.12 | ||
| Q1 25 | $-0.81 | $-0.12 | ||
| Q4 24 | $-0.71 | $-0.14 | ||
| Q3 24 | $-0.73 | $-0.10 | ||
| Q2 24 | $-0.55 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $9.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $1.1B |
| Total Assets | $480.2M | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $9.4M | ||
| Q4 25 | $388.9M | $14.1M | ||
| Q3 25 | $416.1M | $8.8M | ||
| Q2 25 | $291.0M | $11.4M | ||
| Q1 25 | $314.5M | $7.6M | ||
| Q4 24 | $320.6M | $7.3M | ||
| Q3 24 | $298.4M | $12.8M | ||
| Q2 24 | $319.1M | $18.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $139.1M | $1.2B | ||
| Q3 25 | $148.8M | $1.2B | ||
| Q2 25 | $-11.9M | $1.1B | ||
| Q1 25 | $18.9M | $1.1B | ||
| Q4 24 | $21.7M | $1.1B | ||
| Q3 24 | $11.2M | $1.1B | ||
| Q2 24 | $39.3M | $1.1B |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $480.2M | $2.7B | ||
| Q3 25 | $506.9M | $2.8B | ||
| Q2 25 | $372.7M | $3.1B | ||
| Q1 25 | $386.7M | $3.0B | ||
| Q4 24 | $392.3M | $3.0B | ||
| Q3 24 | $363.6M | $3.0B | ||
| Q2 24 | $381.8M | $3.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.18× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.52× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $14.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $14.0M | ||
| Q4 25 | $-25.4M | $76.0M | ||
| Q3 25 | $-26.6M | $13.5M | ||
| Q2 25 | $-23.3M | $23.8M | ||
| Q1 25 | $-40.4M | $13.2M | ||
| Q4 24 | $-18.8M | $52.3M | ||
| Q3 24 | $-25.2M | $13.9M | ||
| Q2 24 | $-29.1M | $10.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 2.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
